Maintaining ‘warm base’ capacity for pandemic preparedness

Vaccine Insights 2024; 3(1), 55–58

DOI: 10.18609/vac.2024.012

Published: 12 April
Kilian Mullett

The COVID-19 pandemic put immense pressure on vaccine manufacturing facilities to rapidly scale up processes to meet demand—could warm base facilities be a solution for future pandemics? Casey Nevins, Assistant Editor, Vaccine Insights, speaks with Kilian Mullett, Senior Director of Commercial Supply Strategies, Pfizer, about challenges and solutions associated with establishing and maintaining a warm base vaccine manufacturing facility.